IP Library Granted Patent US 6,887,232
Granted Patent B2
US 6,887,232 · App. 10/293,226 · Granted May 3, 2005

Closed loop control for intrastromal wavefront-guided ablation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,887,232
App. No.
10/293,226
Granted
May 3, 2005
Kind
B2
Abstract

A closed-loop control system for the intrastromal photoablation of tissue includes an active mirror for individually directing the component beams of a diagnostic laser beam to a focal point on the retina of an eye. The reflected beam is analyzed to identify a distorted wavefront indicative of required corneal corrections, and an induced wavefront indicative of optical aberrations introduced by bubbles formed during tissue ablation. A comparator alters the induced wavefront with a desired wavefront to create a rectified wavefront, and a comparator compares the rectified wavefront with the distorted wavefront to create error signals. The error signals are then used to operate the active mirror and to control an ablation laser until the absence of error signals indicate the required stromal tissue has been photoablated.

Claims (38)

1. A closed-loop system for controlling intrastromal photoablation of stromal tissue of an eye, wherein gas bubbles resulting from the ablation of the tissue introduce induced optical aberrations, said system comprising:

a source for generating an ablation laser beam to photoablate stromal tissue;

a source for generating a diagnostic laser beam, with the diagnostic laser beam including a plurality of component beams;

an active mirror for directing said diagnostic laser beam to a focal spot on the retina of the eye;

a detector for using light of said diagnostic beam reflected from the retina through the bubbles to generate an induced wavefront having characteristics of the induced optical aberrations, together with a distorted wavefront having actual real-time characteristics of the cornea;

a compensator for altering a predetermined desired wavefront by incorporating said induced wavefront therewith to create a rectified wavefront;

a comparator for comparing said rectified wavefront with said distorted wavefront to create an error signal having a plurality of error segments;

a means for reconfiguring said active mirror in response to said plurality of error segments to maintain said focal spot on the retina, wherein said active mirror comprises a plurality of separate reflective elements for individually reflecting respective component beams of the diagnostic beam, and wherein said reconfiguring means individually activates each said reflective element in response to a corresponding segment of said error signal; and

a means for ceasing generation of said ablation beam when said error signal is substantially a nullity.

2. A system as recited in claim 1 wherein said ablation beam is a pulsed laser beam.

3. A system as recited in claim 1 wherein said detector is a Hartmann-Shack sensor unit.

4. A system as recited in claim 1 wherein said desired wavefront is a plane wavefront.

5. A closed-loop system for controlling intrastromal photoablation of tissue in the cornea of an eye, wherein gas bubbles resulting from the ablation of the tissue introduce induced optical aberrations, said system comprising:

a means for detecting an induced wavefront indicative of light passing through the cornea, said induced wavefront including characteristics of the induced optical aberrations;

a means for altering said induced wavefront with a desired wavefront to obtain a rectified wavefront having a plurality of components;

a means for comparing said components of the rectified wavefront with a predetermined distorted wevefront to create an error signal having a plurality of error segments respectively corresponding to components of the rectified wavefront;

a means for using said error signal to activate an ablation laser beam for ablating stromal tissue; and

a means for ceasing generation of the ablation laser beam when au error segments of the error signal are a null.

6. A system as recited in claim 5 wherein said detecting means comprises:

a source for generating a diagnostic laser beam, with the diagnostic laser beam including a plurality of component beams;

an active mirror for directing said diagnostic laser beam to a focal spot on the retina of the eye; and

a detector for using light of said diagnostic beam reflected from the retina through the bubbles to generate respective components for an induced wavefront having characteristics of the induced optical aberrations.

7. A system as recited in claim 6 wherein the detector is a Hartmann-Shack sensor.

8. A system as recited in claim 6 wherein the active mirror comprises a plurality of separate reflective elements for individually reflecting respective component beams of the diagnostic beam.

9. A system as recited in claim 8 wherein the active mirror maintains the focal spot on the retina by separately reconfiguring the reflective elements in response to respective error segments in the error signal.

10. A method for controlling the intrastromal photoablation of tissue of an eye, wherein gas bubbles resulting from, the ablation of tissue introduce induced optical aberrations, the method comprising the steps of:

predetermining a desired wavefront for the eye;

generating a diagnostic laser beam, with the diagnostic laser beam including a plurality of component beams;

using an active mirror to direct the diagnostic laser beam to a focal spot on the retina of the eye, the active mirror having a plurality of separate reflective elements for individually reflecting respective component beams of the diagnostic beam;

using the components of the diagnostic laser beam to identify respective components of an induced wavefront, the induced wavefront being characteristic of the induced optical aberrations;

altering the desired wavefront with the components of the induced wavefront to create a rectified wavefront having respective components;

detecting components of a distorted wavefront with light from the diagnostic beam reflected from the retina, the distorted wavefront having actual real-time characteristics of the cornea;

comparing components of the rectified wavefront with respective components of the distorted wavefront to create a plurality of error segment signals;

reconfiguring respective reflective elements of the active mirror in accordance with the error segment signals to maintain the focal spot of the diagnostic laser beam on the retina;

selectively generating an ablation beam to photoablate stromal tissue; and

ceasing generation of the ablation laser beam when the error segment signals are a null.

11. A method as recited in claim 10 wherein the ablation laser beam is a pulsed laser beam.

12. A method as recited in claim 10 wherein the desired wavefront is a plane wavefront.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2009
From: 20/10 PERFECT VISION AG
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023510/0024 →
CHANGE OF NAME Recorded Aug 10, 2009
From: 20/10 PERFECT VISION OPERATIONS GMBH
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 023065/0970 →
CHANGE OF NAME Recorded Aug 6, 2009
From: 20/10 PERFECT VISION AG
To: 20/10 PERFECT VISION OPERATIONS GMBH
Reel/Frame 023065/0012 →
CHANGE OF NAME Recorded Aug 5, 2009
From: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
To: 20/10 PERFECT VISION AG
Reel/Frame 023056/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2003
From: BILLE, JOSEF
To: 20/10 PERFECT VISION OPTISCHE GERAETE GMBH
Reel/Frame 013680/0805 →